| DOBROTKOVÁ, Viera, Petr CHLAPEK, Pavel MAZÁNEK, Jaroslav ŠTĚRBA a Renata VESELSKÁ. Traffic lights for retinoids in oncology: molecular markers of retinoid resistance and sensitivity and their use in the management of cancer differentiation therapy. BMC Cancer. London: BioMed Central, 2018, roč. 18, č. 1059, s. nestránkováno, 13 s. ISSN 1471-2407. Dostupné z: https://dx.doi.org/10.1186/s12885-018-4966-5. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1490216,
author = {Dobrotková, Viera and Chlapek, Petr and Mazánek, Pavel and Štěrba, Jaroslav and Veselská, Renata},
article_location = {London},
article_number = {1059},
doi = {http://dx.doi.org/10.1186/s12885-018-4966-5},
keywords = {Retinoids; cell differentiation; retinoid resistance; retinoid sensitivity; predictive biomarkers; acute myeloid leukemia; pancreatic ductal adenocarcinoma; breast carcinoma; neuroblastoma},
language = {eng},
issn = {1471-2407},
journal = {BMC Cancer},
title = {Traffic lights for retinoids in oncology: molecular markers of retinoid resistance and sensitivity and their use in the management of cancer differentiation therapy},
url = {https://bmccancer.biomedcentral.com/articles/10.1186/s12885-018-4966-5},
volume = {18},
year = {2018}
}
TY - JOUR
ID - 1490216
AU - Dobrotková, Viera - Chlapek, Petr - Mazánek, Pavel - Štěrba, Jaroslav - Veselská, Renata
PY - 2018
TI - Traffic lights for retinoids in oncology: molecular markers of retinoid resistance and sensitivity and their use in the management of cancer differentiation therapy
JF - BMC Cancer
VL - 18
IS - 1059
SP - nestránkováno
EP - nestránkováno
PB - BioMed Central
SN - 14712407
KW - Retinoids
KW - cell differentiation
KW - retinoid resistance
KW - retinoid sensitivity
KW - predictive biomarkers
KW - acute myeloid leukemia
KW - pancreatic ductal adenocarcinoma
KW - breast carcinoma
KW - neuroblastoma
UR - https://bmccancer.biomedcentral.com/articles/10.1186/s12885-018-4966-5
L2 - https://bmccancer.biomedcentral.com/articles/10.1186/s12885-018-4966-5
N2 - For decades, retinoids and their synthetic derivatives have been well established anticancer treatments due to their ability to regulate cell growth and induce cell differentiation and apoptosis. Many studies have reported the promising role of retinoids in attaining better outcomes for adult or pediatric patients suffering from several types of cancer, especially acute myeloid leukemia and neuroblastoma. However, even this promising differentiation therapy has some limitations: retinoid toxicity and intrinsic or acquired resistance have been observed in many patients. Therefore, the identification of molecular markers that predict the therapeutic response to retinoid treatment is undoubtedly important for retinoid use in clinical practice. The purpose of this review is to summarize the current knowledge on candidate markers, including both genetic alterations and protein markers, for retinoid resistance and sensitivity in human malignancies.
ER -
DOBROTKOVÁ, Viera, Petr CHLAPEK, Pavel MAZÁNEK, Jaroslav ŠTĚRBA a Renata VESELSKÁ. Traffic lights for retinoids in oncology: molecular markers of retinoid resistance and sensitivity and their use in the management of cancer differentiation therapy. \textit{BMC Cancer}. London: BioMed Central, 2018, roč.~18, č.~1059, s.~nestránkováno, 13 s. ISSN~1471-2407. Dostupné z: https://dx.doi.org/10.1186/s12885-018-4966-5.
|
